Publications

Chronic urticaria (CU) is characterized by wheals and/or an-gioedema for more than 6 weeks, with a point prevalence of 0.1-1.4% (1, 2). CU is classified as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), which can oc-cur simultaneously or independently (3). In CSU patients, con-comitant CIndU has been associated with severe, long-lasting and/or antihistamine-resistant CSU (4). Omalizumab, an an-ti-IgE monoclonal antibody, can improve both CSU and CIndU in the same patients (5, 6). However, its efficacy in CSU patients with several subtypes of CIndU is poorly characterized (6, 7). Here, we describe six patients with antihistamine-resistant CSU and multiple CIndUs (table I) treated with 300 mg omalizumab monthly and followed up for a period of 3-11 months.